期刊
SEMINARS IN CANCER BIOLOGY
卷 35, 期 -, 页码 133-144出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2015.08.005
关键词
AR-targeting therapies; Therapy resistance mechanisms; Target modification; Bypass signalling; Histologic transformation; Cancer stem cells
类别
资金
- Austrian Science Fund (FWF) [P26799-B23]
- Austrian Science Fund (FWF) [P26799] Funding Source: Austrian Science Fund (FWF)
Androgen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches for AR inactivation include chemical castration, inhibition of androgen synthesis and AR antagonists (anti-androgens). However, treatment resistance occurs for which an important number of therapy escape mechanisms have been identified. Herein, we summarise the current knowledge of molecular mechanisms underlying therapy resistance in prostate cancer. Moreover, the tumour escape mechanisms are arranged into the concepts of target modification, bypass signalling, histologic transformation, cancer stem cells and miscellaneous mechanisms. This may help researchers to compare and understand same or similar concepts of therapy resistance in prostate cancer and other cancer types. (C) 2015 The Authors. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据